Anagram Therapeutics, Inc.
Hugh Wight has a diverse work experience spanning over several companies in the biotechnology and pharmaceutical industry. Hugh currently holds the position of Chief Corporate Development Officer at Anagram Therapeutics, Inc. where they work closely with the CEO and Board of Directors to drive the long-range corporate strategy for product development and financing. In this role, they provide strategic and technical leadership, as well as maintains partnerships with biotechnology and pharmaceutical companies.
Prior to joining Anagram Therapeutics, Inc., Hugh worked as an Independent Consultant. Hugh has also held positions at Allena Pharmaceuticals, Inc., Alcresta, Inc., Alnara Pharmaceuticals, Inc., Altus Pharmaceuticals, Inc., Alkermes, Inc., InSite Vision, Inc., and Genetics Institute, Inc. Their roles ranged from Senior Vice President and Vice President in Technical Operations to Director in Quality Systems. In these positions, they led various teams, managed manufacturing operations, and oversaw product development and regulatory interactions.
Overall, Hugh Wight has a wealth of experience in strategy development, operations management, and technical leadership, making him a valuable asset in the biotechnology and pharmaceutical industry.
Hugh Wight attended the University of Maine from 1983 to 1987, where they earned a Bachelor of Science degree in Microbiology.
This person is not in any teams
Anagram Therapeutics, Inc.
Anagram is a clinical stage company leveraging proprietary enzyme technologies and expertise in gastrointestinal diseases to solve complex problems and advance a pipeline of products that can make a life-changing impact for people and their families living with cystic fibrosis and other rare diseases. Malabsorption syndromes and nutrient metabolism disorders prevent the body from properly processing or absorbing certain fats, sugars, proteins, vitamins or other key nutrients. ANG003, Anagram’s lead product is intended for the treatment of malabsorption and exocrine pancreatic insufficiency and is a new class of broad-spectrum digestive enzyme replacement therapy.